Warfarin anticoagulation can prevent ischemic stroke and peripheral embolism in atrial fibrillation (AF) patients. AF management guidelines in Western countries recommend target prothrombin time-international normalized ratio (PT-INR) levels of 2-3, irrespective of age and CHADS2 score [1] . However, racial differences have an impact on the risk of intracranial hemorrhage (ICH) under warfarin treatment, which is higher in Asians than in Caucasians [2] . Therefore, optimal anticoagulation therapeutic ranges should consider racial differences [3] . The J-RHYTHM Registry tracked 2-year clinical outcomes and anticoagulation levels for over 7500 patients with nonvalvular AF (NVAF) [4] [5] [6] .
Statistical analysis
Categorical and consecutive data are presented as number (%) and mean AE standard deviation, respectively. The chi-square and unpaired t-tests were used for group comparisons. INRs at the event or closest prior date were used for cases and INRs at the same followup period were used for event-free controls. ORs with 95% confidence intervals (CIs) were calculated by logistic regression with INR and CHADS2 score as variables. Similar to previous reports [6, 7] , INRs were categorized by 0.2 and 0.5 INR steps for ischemic stroke/SE and ICH, respectively. The OR at each INR category was normalized to 1.0 at an INR range including 2.0 (1.8 < INR 2.0 for stroke/SE and 1.5 < INR 2.0 for ICH). Statistical significance was set at p < 0.05.
Results
During 2 years of warfarin treatment, 97 ischemic stroke/SE and 49 ICH events occurred in 6404 NVAF patients. Table 1 shows the characteristics of patients with and without these events. Compared with controls, ischemic stroke/SE patients were older and had higher CHADS2 scores with a greater prevalence of stroke/ transient ischemic attack (TIA) history. ICH patients were older and had higher CHADS2 scores with greater prevalence of congestive heart failure and stroke/TIA history.
Ischemic stroke/TIA and ICH occurred at a median follow-up of 318 AE 181 days and 335 AE 215 days, respectively. INR at the event was obtained in 59 ischemic stroke/SE and 41 ICH patients. Among the remaining patients, the mean time-lag between events and the closest INR was 38 AE 35 days (n = 38) and 58 AE 59 days (n = 8), respectively. Using these PT-INRs, ORs for ischemic stroke/SE and ICH were estimated as a function of INR. Fig. 1 shows ORs for ischemic stroke/SE and ICH as compared to an INR including 2.0 after adjustment for CHADS2 score, and the detailed risk ratios are shown in Table 2 . We observed no significant interaction between age and INR-risk relationships (data not shown).
The risk of ischemic stroke/SE rose gradually as INR values fell below 2.0 and steeply as they fell below 1. 
Discussion
This study explored the relation of anticoagulation levels to ischemic stroke/SE and ICH for primary and secondary prevention in Japanese NVAF patients. The large size, prospective design, and analysis of event-nearest INRs emphasize study significance [7, 8] . While the INR-risk relationships for ischemic stroke/SE were virtually identical to those in Westerners, ICH relationships shifted leftward by approximately 0.5 of INR.
Two retrospective studies suggested that appropriate INRs for minimizing major hemorrhages in elderly Japanese NVAF patients with a history of stroke/TIA [9] or high CHADS2 score !2 [10] would be lower than in Westerners. The present study supports this notion for many Japanese NVAF patients, showing an occurrence of ICH approximately four times greater at an INR >2.5 than at an INR of 1.5-2.0.
However, an important issue emerged regarding the lowest effective anticoagulation intensity for Japanese NVAF patients. We observed a tendency of gradual increase in risk of ischemic stroke/ SE below an INR of 2.0, similar to Westerners. Moreover, no significant interaction was observed between patient age and INRstroke/SE risk relationships. By contrast, the prior retrospective studies observed no stroke/SE increase in the 1.5-2.0 INR range [9, 10] . Differences in patient characteristics, study design (prospective/retrospective and multicenter/single center), and cohort size may explain this apparent difference.
Despite being large, the present study is not statistically powerful enough to determine risk differences around an INR of 2.0 and by patient age. Therefore, the lowest effective anticoagulation intensity for Japanese NVAF patients requires further study with longer follow-ups [11] .
Limitations include the observational design, physician-determined anticoagulation levels, and limited 2-year follow-up. In addition, the number of patients with INR >2.5 was relatively small as compared with other categories. Although limited, this is the largest study providing fundamental data on INR-event relationships in Japanese NVAF patients.
Conclusions
In Japanese NVAF patients as compared with Westerners, the estimated INR-risk relationships were virtually identical for ischemic stroke/SE but shifted leftward by approximately 0. 
